About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT01869608

Postpartum Screening of Type 2 Diabetes

Gestational diabetes mellitus (GDM) complicates 5 to 30 % of pregnancies. GDM is defined as hyperglycemia with onset or first recognition during pregnancy. Because it is a forerunner of type 2 diabete...

Lead sponsor: Université de Sherbrooke•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Université de Sherbrooke

Collaborators

The Lawson Foundation

Age

18 - 45 years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•Women aged between 18 and 45 years;
•Having a positive diagnosis of gestational diabetes mellitus (IADPSG criteria);
•Treated with diet or insulin;
•Have given birth to a child at term; gestational age \> 37 weeks;
•Have been followed during her pregnancy by a physician who delivers in CHUS;
•Have signed the consent form.

Exclusion Criteria

•History of glucose intolerance or diabetes before the pregnancy;
•Have presented another obstetrical pathology during the pregnancy;
•* Severe gestational high blood pressure with proteinuria;
•* Delayed intrauterine development syndrome;
•* Pregnancy with more than a foetus;
•* Drug addiction;
•* Had complications during the delivery such as:
•Moderate to severe postpartum bleeding;
•Surgery in postpartum (curettage, hysterectomy, etc.).

Related studies

Effect of the Digital Livsstilsverktyget in Conjunction With a Large Language Model on the Prevention of Type 2 Diabetes

NCT07659535 · Type 2 Diabetes

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT07011147 · Type 1 Diabetes (T1D), Type 2 Diabetes, and more

RECRUITINGPhase 3

Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients

NCT07581145 · Foot Ulcer Due to Type 2 Diabetes Mellitus

Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD

NCT07187830 · Chronic Kidney Disease in Type 2 Diabetes, Obesity & Overweight

LINK-IT: Leveraging vIdeos and commuNity Health worKers to Improve Diabetes OuTcomes

NCT06319716 · Type 2 Diabetes

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 1, 2019Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment121

Start dateApr 2014

Last updatedMay 1, 2019

Condition

Type 2 Diabetes

Locations shown

Clinical Research Center Étienne-Le Bel of the Sherbrooke University Hospital

Sherbrooke, Quebec

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 1, 2019Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions